Three trials presented at ASCO GI 2025 will change practice and improve the treatment of colorectal cancer, according to experts.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

This week was loaded with earnings releases of many large drugmakers. Novo Nordisk NVO, Merck MRK, Pfizer PFE, Eli Lilly LLY, ...

Day One Bio aims to bring new cancer therapies to pediatric patients faster amid evolving financial incentives, such as the ...

The AI-driven tools are getting better at recommending biomarker-targeted therapies, but experts warn they aren't ready for prime time.

Patients may require life-long monitoring and a collaborative engagement with subspecialists to keep well in the long -term,” ...

In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve treatment outcomes for patients with high-risk early-stage triple-negative ...